Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EEF2K | O00418 | 4/20 | 0.53 |
| ▸ | ATM | Q13315 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | ITGB3 | P05106 | 9/20 | 0.46 |
| ▸ | ITGAV | P06756 | 9/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3310158 | 0.76 | EEF2K (0.66) | EEF2KATML3MBTL1ALDH1A1ITGB3 | |
| SCHEMBL644240 | 0.76 | EEF2K (0.66) | EEF2KATML3MBTL1ALDH1A1ITGB3 | |
| SCHEMBL28404274 | 0.76 | ATM (0.76) | EEF2KATML3MBTL1ALDH1A1ITGB3 | |
| SCHEMBL2202179 | 0.74 | ATM (0.58) | EEF2KATML3MBTL1ALDH1A1ITGB3 | |
| SCHEMBL6945237 | 0.72 | KCNA5 (0.57) | EEF2KATML3MBTL1ALDH1A1 | |
| SCHEMBL11679882 | 0.71 | ALDH1A1 (0.46) | ALDH1A1 | |
| SCHEMBL7572130 | 0.70 | ATM (0.76) | EEF2KATML3MBTL1ALDH1A1ITGB3 | |
| SCHEMBL19385953 | 0.70 | ADAMTS4 (0.45) | EEF2KATML3MBTL1ALDH1A1ITGB3 | |
| SCHEMBL6071205 | 0.69 | ALDH1A1 (0.41) | ALDH1A1KDM4C | |
| SCHEMBL6953103 | 0.69 | EEF2K (0.56) | EEF2KATML3MBTL1ALDH1A1ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1297546-C | N- (arylsulfonyl) -beta-amino acid derivatives with substituted aminomethyl group, process for their preparation and pharmaceutical compositions containing them | SANOFI SYNTHELABO (FR) | 2007-01-31 | — | — | CN | disclosed |
| US-7157454-B2 | Derivatives of n-(arylsulfonyl)beta-aminoacids comprising a substituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2007-01-02 | — | — | US | disclosed |
| CN-1541211-A | Derivatives of N-(arylsulfonyl) beta-aminoacids comprising substituted aminomethyl group, prepn. method thereof and pharmaceutical compsns. contg same | ʥŵ��-�ϳ�ʵ���ҹ�˾ | 2004-10-27 | — | — | CN | disclosed |
| US-20040116353-A1 | Derivatives of n-(arylsulfonyl)beta-aminoacids comprising a substituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing same | SANOFI (FR) | 2004-06-17 | — | — | US | disclosed |
| US-6610882-B2 | Affinity for bradykinin receptors; antithrombotics | SANOFI-SYNTHELABO (FR) | 2003-08-26 | — | — | US | disclosed |
| US-20030073641-A1 | Novel N-(arylsulphonyl) amino acid derivatives, process for their preparation and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2003-04-17 | — | — | US | disclosed |
| US-20020115685-A1 | Novel N-(arylsulphonyl) amino acid derivatives, process for their preparation and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2002-08-22 | — | — | US | disclosed |
| US-6433185-B1 | ANTIINFLAMMATORY AGENTS; ANALGESICS | SANOFI-SYNTHELABO (FR) | 2002-08-13 | — | — | US | disclosed |
| US-6313120-B1 | TREATMENT OR PREVENTION OF DISEASES INVOLVING BRADYKININ RECEPTORS | SANOFI-SYNTHELABO (FR) | 2001-11-06 | — | — | US | disclosed |
| US-6100278-A | COMPOUNDS HAVING AFFINITY FOR BRADYKININ RECEPTORS; ANTIINFLAMMATORY AGENTS | SANOFI-SYNTHELABO (FR) | 2000-08-08 | — | — | US | disclosed |
| US-6015812-A | N-(arylsulphonyl)amino acid derivatives having bradykinin receptor affinity | SANOFI-SYNTHELABO (FR) | 2000-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115685-A1 | Novel N-(arylsulphonyl) amino acid derivatives, process for their preparation and pharmaceutical compositions containing them | CYP2C9, ADRM1, ADRA1D | EEF2K 2608/4885ATM 4322/4885L3MBTL1 4719/4885 |
| US-20030073641-A1 | Novel N-(arylsulphonyl) amino acid derivatives, process for their preparation and pharmaceutical compositions containing them | CYP2C9, ADRM1, ADRA1D | EEF2K 2608/4885ATM 4322/4885L3MBTL1 4719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.